rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ARWR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Stifel cuts Arrowhead Pharma stock price target on Tryngolza launch
      Nov 13Investing.comARWR
      Arrowhead Pharma earnings on deck: REDEMPLO launch in focus
      Nov 12Investing.comARWR
      H.C. Wainwright reiterates Arrowhead Pharma stock rating on AHA data
      Nov 11Investing.comARWR
      Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
      Nov 7Yahoo FinanceARWR
      Cantor Fitzgerald reiterates Arrowhead Pharma stock rating on trial data
      Oct 15Investing.comARWR
      Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform (NASDAQ:ARWR)
      Oct 15Seeking AlphaARWR
      H.C. Wainwright reiterates Arrowhead Pharma stock rating on tau data
      Oct 15Investing.comARWR
      Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
      Oct 14Yahoo FinanceARWR
      Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
      Oct 7Yahoo FinanceARWR
      Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
      Sep 29Yahoo FinanceARWR
      Goldman Sachs initiates Arrowhead Pharma stock coverage with neutral rating
      Sep 24Investing.comARWR
      Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
      Sep 18Yahoo FinanceARWR
      Arrowhead Achieves Clinical Validation for New Drug Platform
      Sep 16BenzingaARWR
      ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?

      ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.

      Sep 15Yahoo FinanceARWR
      Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

      PASADENA, Calif., September 15, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (AP

      Sep 15Yahoo FinanceARWR
      Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) presented detailed results from the randomized, double-blind, placebo-controlled Phase 3 SHASTA-3 and SHASTA-4 studies in 757 adults with severe hypertriglyceridemia. Four quarterly 25-mg doses of plozasiran produced median triglyceride reductions of 79% and 81% at Month 12, compared with approximately 27% for placebo in each study. A prespecified pooled analysis showed […]

      Sep 4Yahoo FinanceARWR
      Stifel reiterates Buy rating on Arrowhead Pharma stock at $104
      Aug 31Investing.comARWR
      RBC Capital reiterates Arrowhead Pharma stock rating on ESC data
      Aug 31Investing.comARWR
      Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

      PASADENA, Calif., August 30, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a Hot Line Late-Breaking Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.

      Aug 30Yahoo FinanceARWR
      Arrowhead Pharmaceuticals director sells $173,920 in stock
      Aug 21Investing.comARWR

      This is the newest page. Registered accounts read further back.